LEO Pharma Launches Open Innovation in Ontario to Support the Innovation Ecosystem in the Province
BALLERUP, Denmark--(BUSINESS WIRE)--Nov 21, 2019--
LEO Pharma A/S, a global leader in medical dermatology, today announced the launch of Open Innovation in Ontario, Canada, at the University of Toronto.
LEO Pharma Open Innovation is a collaborative space created to explore the latest research and potential partnerships by using disease-relevant in-vitro assays as an initial stepping stone with the goal to find next-generation treatments for skin diseases, such as psoriasis and atopic dermatitis.
Open Innovation allows any organization insights and access to LEO Pharma’s unique research tools to test external molecules for disease-relevant effects, but without the obligation for a partner to disclose confidential information, such as molecular structure or intellectual property. The classic corporate research collaboration usually follows a closed process, focuses only on business benefits and limits the partners continued opportunities.
“LEO Pharma hopes to set a new standard for collaborations and hopes others in the industry will follow,“ said Niclas Nilsson, Head of Open Innovation, LEO Pharma A/S. “By openly disclosing assays offered and areas of corporate interests, LEO Pharma’s hope is that someone will have a novel resource, piece of information or an idea toward a potential solution for dermatology patients.”
The launch is being announced today as part of an Open Innovation: Collaborative Partnerships seminar with participation of Rachel Simeon, Assistant Deputy Minister of Research, Science and Commercialization Division; Jeppe Fredslund, Head of Trade, Danish Trade Council; Nilsson; Kristian Fick, President, LEO Pharma Canada; Jason Field, President and CEO, Life Sciences Ontario, and representatives from the University of Toronto and Danish Trade Council.
“This collaboration further supports a provincial life sciences ecosystem that encourages innovation impacting the health of Canadians and the sustainability of our healthcare system,” said Field. “Life Sciences Ontario advocates for the life sciences community and serves as a hub of connectivity to enable life sciences companies to thrive and grow here at home, creating Made-in-Ontario success stories. We look forward to what LEO Pharma Open Innovation can bring to our region in terms of potential advances in dermatology.”
LEO Pharma’s footprint in Canada includes the first North American LEO Innovation Lab, located in Toronto. The LEO Innovation Lab develops digital solutions for patients living with skin conditions, with an aim to go beyond medicinal interventions and instead explore holistic answers to help prevent and manage health issues.
“LEO Pharma is committed to bringing innovative solutions to patients in Canada, as well as advancing life sciences through investments in clinical trials across Canada, including within Ontario,” said Fick. “We hope to fuel innovation in medical dermatology and help others see the value of public-private partnerships.”
About LEO Pharma
LEO Pharma A/S helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005412/en/
CONTACT: Rhonda Sciarra
Global External Communications
Global External Communications
+45 3140 6180
KEYWORD: EUROPE DENMARK NORTH AMERICA CANADA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE PHARMACEUTICAL RESEARCH
SOURCE: LEO Pharma A/S
Copyright Business Wire 2019.
PUB: 11/21/2019 09:05 AM/DISC: 11/21/2019 09:05 AM